Product Description
Molecular Formula: C12H15N5O3
Molecular Weight: 277.28
Welcome to contact: +86 18046216202 (Jessica)
+86 592 5789920 (Office Line)
AI Product Description
*The following content is generated by AI and is for reference only.
Entecavir, manufactured under Good Manufacturing Practice (GMP) standards, is a potent nucleoside analogue antiviral medication primarily indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults and pediatric patients. As a guanosine analogue, it works by selectively inhibiting the viral DNA polymerase, thereby blocking the replication of the HBV genome without affecting human cellular DNA synthesis. This mechanism effectively reduces viral load, improves liver function tests, and decreases the risk of disease progression to cirrhosis or hepatocellular carcinoma.
The drug is available in oral tablet and solution forms, typically administered once daily on an empty stomach to ensure optimal bioavailability. Clinical efficacy has been well-documented across various patient populations, including those with HBeAg-positive and HBeAg-negative chronic hepatitis B, as well as lamivudine-resistant strains. However, strict adherence to GMP guidelines during production ensures high purity, potency, and safety profiles, minimizing impurities that could lead to adverse reactions.
Despite its therapeutic benefits, several critical precautions must be observed. Patients should not discontinue Entecavir abruptly, as this may precipitate severe acute exacerbations of hepatitis. Renal impairment requires dose adjustments based on creatinine clearance, as the drug is primarily excreted unchanged by the kidneys. Furthermore, there is a rare but serious risk of lactic acidosis and severe hepatomegaly with steatosis, particularly in patients with underlying liver decompensation or HIV co-infection. While generally well-tolerated, common side effects include headache, fatigue, dizziness, and nausea. Long-term monitoring of liver enzymes, viral markers, and renal function is essential throughout therapy. Pregnant or breastfeeding women should consult healthcare providers regarding potential risks, as data remains limited. Overall, when used according to medical supervision and GMP specifications, Entecavir represents a cornerstone therapy in managing chronic hepatitis B, significantly improving long-term clinical outcomes and quality of life for millions of patients worldwide.